GlassScriptPhysician profile
Myint S Oo
NPI 1215940143
$4,074.19
in general payments reported to CMS, 2019-2025
28 companies · $950 in 2025
The $950 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $305 · 2021: $431 · 2022: $519 · 2023: $968 · 2024: $519 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $494.14 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $468.03 | 2019-2024 | Jornay Pm |
| Novo Nordisk INC | $374.90 | 2022-2025 | Wegovy |
| Glaxosmithkline, LLC. | $365.16 | 2019-2025 | Arexvy, Bexsero, Pediarix |
| Sanofi Pasteur INC. | $349.20 | 2019-2025 | |
| Corium, LLC | $283.12 | 2021-2024 | Azstarys |
| Tris Pharma INC | $254.35 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Merck Sharp & Dohme LLC | $252.82 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Supernus Pharmaceuticals, INC. | $200.49 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $184.25 | 2019-2022 | |
| Sobi, INC | $139.04 | 2019-2022 | |
| Cranial Technologies, INC | $108.13 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $96.49 | 2025 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $89.39 | 2025 | Neffy |
| Neos Therapeutics, LP | $76.60 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $48.70 | 2025 | Flucelvax |
| Arbor Pharmaceuticals, INC. | $42.99 | 2019 | |
| Biomarin Pharmaceutical INC. | $36.67 | 2024-2025 | Voxzogo 1.2mg |
| Kaleo, INC. | $34.98 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $26.98 | 2024 | Koselugo |
| Astrazeneca Pharmaceuticals LP | $25.36 | 2023 | Flumist Quadrivalent |
| Acadia Pharmaceuticals INC | $21.17 | 2023 | Daybue |
| Xeris Pharmaceuticals, INC. | $18.92 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.30 | 2022 | |
| Phadia US INC. | $17.17 | 2025 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $16.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.78 | 2023 | Airduo Digihaler |
| Adlon Therapeutics L.P. | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myint Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.